Presidio Pharmaceuticals Obtains $26,000,000 Series B Round

  • Feed Type
  • Date
  • Company Name
    Presidio Pharmaceuticals
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158
  • Company Description
    Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Dr. Omar K. Haffar, President and CEO of Presidio Pharmaceuticals said, “The proceeds of this financing will be used to advance two of our programs into human clinical studies, continue establishing alliances with outside partners, and expand our product portfolio through additional in-licensing transactions.”
  • M&A Terms
  • Venture Investor
    Panorama Capital
  • Venture Investor
    Baker Brothers Investments
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Nexus Medical Partners
  • Venture Investor
    Ventures West
  • Venture Investor
    Sagamore Bioventures

Trending on Xconomy